Politicians consistently wage high-profile battles over prescription drugs and the companies that make them. The dilemma is balancing the pharmaceutical industry's need to make a profit with the public's need for affordable medical care. This book presents analyses of the federal government's regulation of the drug industry and the arguments over the prices of prescription drugs.

"Addressing a number of practical implications for the promotion of the pharmaceutical industry, this book will be of enormous interest to students, researchers and academics specializing in science and technology studies, and the management of technology and innovation. Practitioners, managers, and policy planners within the pharmaceutical industry will also deem this book invaluable."--BOOK JACKET.

In recent years, many factors have combined to change the operating environment of the international pharmaceutical industry leading to greater specialisation and sophistication. This new edition will give an update of the different opportunities in drug discovery and development and the scientific, medical or other specialist training needed to accomplish them. The scope of this edition has been broadened to encompass all major roles, including marketing and sales.

This book examines the strategic aspects of outsourcing in relation to the firm. It provides a holistic view of the outsourcing process, starting with conceptualisation, through to implementation and management of the process. Although the book is based on a case study of the pharmaceutical industry, the general principles derived from the Strategic Sourcing Model are generic in nature and the model can be applied to instances of outsourcing in other industries.

This practical guide for advanced students and decision-makers in the pharma and biotech industry presents key success factors in R&D along with value creators in pharmaceutical innovation. A team of editors and authors with extensive experience in academia and industry and at some of the most prestigious business schools in Europe discusses in detail the innovation process in pharma as well as common and new research and innovation strategies. In doing so, they cover collaboration and partnerships, open innovation, biopharmaceuticals, translational medicine, good manufacturing practice, regulatory affairs, and portfolio management. Each chapter covers controversial aspects of recent developments in the pharmaceutical industry, with the aim of stimulating productive debates on the most effective and efficient innovation processes. A must-have for young professionals and MBA students preparing to enter R&D in pharma or biotech as well as for students on a combined BA/biomedical and natural sciences program.

Blending the authors’ considerable experiences with those of interviewees and with their retrospective and forward-looking perspectives, this volume explains how to apply Knowledge Management in a variety of environments in order to achieve improved efficiency, better decision making and enhanced innovation. This is achieved by exploring Knowledge Management tools and techniques within the changing landscape of the pharmaceutical industry.

2011 Updated Reprint. Updated Annually. China Pharmaceutical Chemicals Producers Directory

With a focus on case studies of R&D programs in a variety of disease areas, the book highlights fundamental productivity issues the pharmaceutical industry has been facing and explores potential ways of improving research effectiveness and efficiency. Takes a comprehensive and holistic approach to the problems and potential solutions to drug compound attrition Tackles a problem that adds billions of dollars to drug development programs and health care costs Guides discovery and development scientists through R&D stages, teaching requirements and reasons why drugs can fail Discusses potential ways forward utilizing new approaches and opportunities to reduce attrition

Multivariate Analysis in the Pharmaceutical Industry provides industry practitioners with guidance on multivariate data methods and their applications over the lifecycle of a pharmaceutical product, from process development, to routine manufacturing, focusing on the challenges specific to each step. It includes an overview of regulatory guidance specific to the use of these methods, along with perspectives on the applications of these methods that allow for testing, monitoring and controlling products and processes. The book seeks to put multivariate analysis into a pharmaceutical context for the benefit of pharmaceutical practitioners, potential practitioners, managers and regulators. Users will find a resources that addresses an unmet need on how pharmaceutical industry professionals can extract value from data that is routinely collected on products and processes, especially as these techniques become more widely used, and ultimately, expected by regulators. - Targets pharmaceutical industry practitioners and regulatory staff by addressing industry specific challenges - Includes case studies from different pharmaceutical companies and across product lifecycle of to introduce readers to the breadth of applications - Contains information on the current regulatory framework which will shape how multivariate analysis (MVA) is used in years to come

First published in 1984, this book examines corporate crime in the pharmaceutical industry. Based on extensive research, including interviews with 131 senior executives of pharmaceutical companies in the United States, the United Kingdom, Australia, Mexico and Guatemala, the book is a major study of white-collar crime. Written in the 1980s, it covers topics such as international bribery and corruption, fraud in the testing of drugs and criminal negligence in the unsafe manufacturing of drugs. The author considers the implications of his findings for a range of strategies to control corporate crime, nationally and internationally.